The protein Ser/Thr phosphatase family contains three enzymes called PP2A, PP4, and PP6 with separate biological functions inferred from genetics of the yeast homologues Pph21/22, Pph3, and Sit4. These catalytic subunits associate with a common subunit called ␣4 (related to yeast Tap42). Here, we characterized recombinant PP6 and PP2A catalytic monomers and ␣4⅐phosphatase heterodimers. Monomeric PP6 and PP2A showed identical kinetics using either p-nitrophenyl phosphate (pNPP) or 32 P-myelin basic protein (MBP) as substrates, with matching K m and V max values. Using pNPP as substrate, PP6 and PP2A gave the same IC 50 with active site inhibitors okadaic acid, microcystin-LR, calyculin A, and cantharidin. However, with MBP as substrate, PP6 was inhibited at 5-fold lower concentrations of toxins relative to PP2A, suggesting PP6 might be a preferred in vivo target of toxins. Heterodimeric ␣4⅐PP6 and ␣4⅐PP2A were starkly different. With MBP as substrate the ␣4⅐PP2A heterodimer had a 100-fold higher V max than ␣4⅐PP6, and neither heterodimer was active with pNPP. Thus, these phosphatases are distinguished by their different responses to allosteric binding of the common regulatory subunit ␣4. Transient expression of ␣4 differentially increased or decreased phosphorylation of endogenous phosphoproteins, consistent with opposing effects on PP2A and PP6.
The PPP family of serine/threonine protein phosphatases comprises PP1, 2 PP2A, PPP3 (calcineurin), PP4, PP5, PP6, and PP7 (1) (2) (3) (4) . These phosphatases are closely related in sequence but can be distinguished functionally based on inhibition by small molecule toxins such as okadaic acid (OA), microcystin-LR (MCLR), and calyculin A. The three-dimensional structure of PP1 has been determined with each of these three toxins bound at the active site (5-7). Phosphatases PP1, PP2A, PP4, and PP5 are known to be sensitive to inhibition by okadaic acid, with PP2A and PP4 inhibited at lower (nanomolar) concentrations relative to the others (8 -10) . To date no assays of PP6, so no inhibitor sensitivity, have been reported, but PP6 is presumed sensitive based on sequence similarity. On the other hand, phosphatases calcineurin and PP7 are not inhibited even by micromolar concentrations of okadaic acid (4, 8, 11) . The three-dimensional structure of calcineurin revealed the same overall protein fold as seen in PP1, despite the differences in toxin binding.
Members of the type 2A group of phosphatases (PP2A, PP4, and PP6) are the most closely related in sequence (ϳ50% identity). Type 2A phosphatase activity has been implicated in the regulation of metabolism, transcription, translation, DNA replication, cell cycle progression (G 2 -M), cell growth, and apoptosis (12) (13) (14) . In most cases, conclusions depend entirely on the inhibitory effects of nanomolar concentrations of okadaic acid, but this does not distinguish PP2A from PP4 or PP6.
Genetic studies in yeast demonstrate separate functions for each of the homologues (15) . Knowledge of the structure to function relationship among PP2A, PP4, and PP6 will help to dissect and understand their individual functions in living cells. Current information on the biochemical properties of type 2A protein phosphatases comes from studies of PP2A and PP4 purified from tissues and assayed with artificial substrates (e.g. Refs. 9 and 14) . The monomeric PP2A and PP4 catalytic subunits isolated using room temperature alcohol precipitation hydrolyze the small molecule p-nitrophenyl phosphate, as well as various Ser/Thr phosphopeptides, and phosphoproteins such as phosphorylase, casein, or histone (9, 14) . In contrast, PP6 activity has not been documented with either a partially purified preparation (14) or recombinant PP6 expressed in bacteria, which is inactive (16) .
The metazoan regulatory subunit ␣4 is unique because it binds to all three type 2A phosphatases, PP2A, PP4, and PP6. ␣4 is the homologue of the yeast protein Tap42. Tap42 binds yeast phosphatases Sit4 (PP6) and Pph3 (PP4) and Pph21/22 (PP2A) (17) . The effects of Tap42 or ␣4 binding on phosphatase activity have been controversial. Under conditions where the kinase target of rapamycin (TOR) is active, Tap42 binds Sit4 and Pph21/22 phosphatases. Because the phosphorylation of the transcription factor Gln3 and the permease regulator Npr1 increases under these conditions, the conclusion is that Tap42 inhibits Sit4 phosphatase activity (18 -21) . Further, nuclear accumulation of Msn2p in tap42 106 mutants or in wild type cells treated with rapamycin has been interpreted as evidence for TOR-dependent Tap42 inhibition of Pph21/21. On the other hand, mammalian ␣4 binds PP2A, PP4, and PP6 in yeast 2-hybrid assays as well as in co-immunoprecipitations and glutathione S-transferase pulldown assays (22) (23) (24) (25) . Glutathione S-transferase-␣4⅐PP2A exhibits 9:1 higher activity with myelin basic protein as substrate relative to phosphorylase (24) . Epitope-tagged PP2A co-immunoprecipitates with endogenous ␣4 from COS7 cells, and these precipitates display phosphatase activity toward phospho-MBP (26) . Furthermore, transient overexpression of tagged ␣4 in COS7 cells results in a 50% reduction in endogenous eEF-2 phosphorylation (27) . The results from these studies support the idea that ␣4 modifies PP2A substrate specificity rather than simply acting as an inhibitor, but the kinetic properties of the PP⅐␣4 heterodimers are not known.
In this study, we expressed monomeric His 6 -PP6 and His 6 -PP2A using Sf9 cells and purified active recombinant phosphatases. We compared substrate specificities of these two phosphatases using different substrates and tested inhibition by a diverse set of active site toxins. Furthermore, we co-expressed His 6 -tagged ␣4 with untagged PP6 or PP2A catalytic subunits and purified the heterodimers and compared their phosphatase activities and inhibition by toxins. The results show that PP6 is more sensitive to inhibition by toxins than PP2A, and the properties of PP6 and PP2A catalytic subunits are modified quite differently by interaction with the ␣4 regulatory subunit. Transient overexpression of ␣4 in cells enhanced phosphorylation of some proteins, whereas it depressed phosphorylation of others, consistent with opposing actions with different phosphatases.
EXPERIMENTAL PROCEDURES
Cell and Cell Culture-Sf9 cells were obtained from the ATCC (CRL-1711) and grown in SF-900 II medium with 10% fetal bovine serum and 1ϫ antibiotic/antimycotic from Invitrogen. Prior to high titer virus production, the cells were dropped to 0% serum by stepwise removal of serum from cells at each split in five steps. Cells were grown in baffled spinner flasks (Fisher) starting at a density of 0.5 ϫ 10 6 cells/ml. COS7 cells were grown in 10% fetal bovine serum/Dulbecco's modified Eagle's medium (Invitrogen) at 37°C in a humidified incubator with 5% CO 2 .
Viral Production-Murine ␣4 was cloned into pFastBacHTb vector (Invitrogen) downstream of the His 6 tag using BamHI and EcoRI sites. Human PP2A and PP6 catalytic subunits were cloned into pFastBac (Invitrogen) (for co-expression with ␣4) or pFastBac-HTb (for producing monomer) using BamHI-EcoRI sites. Ligation into DH10 bacmid was determined by PCR amplification of inserts using M13 forward and reverse primers. Baculovirus and high titer virus were made according to the manufacturer's protocol (Invitrogen). Viral titer (plaque-forming unit/ml) was determined by the University of Virginia Tissue Culture Core Facility. Final high titer virus stock was stored in 5% fetal bovine serum and kept at 4°C in the dark.
Protein Production and Purification-Dimeric complexes were made by co-infection with a virus for His 6 -tagged regulatory subunit ␣4 plus a virus for either PP2A or PP6 at a multiplicity of infection of 5 into 300 ml of cells at a density of 2.5 ϫ 10 6 cells/ml. Expression of monomeric His 6 -PP2A or His 6 -PP6 used viruses at a multiplicity of infection of 10 in 300 ml of Sf9 cells at a density of 3 ϫ 10 6 cells/ml. Prior to infection, cells were centrifuged at 1000 rpm for 5 min in a clinical benchtop centrifuge, and medium was removed. Virus was mixed with serum-free medium to a final volume of 30 ml and added to cells, and the tube was rocked on a platform for 1 h at room temperature. This suspension was added to a baffled spinner flask and the volume taken up to 300 ml with Sf-900 II media containing 1ϫ antibiotic/antimycotic (Invitrogen). Cells were incubated at 27°C for 48 -55 h (for monomeric catalytic PP2A or PP6 subunits) or 65-72 h (dimeric complexes) with spinning at 300 -500 rpm.
Protein purification was done by collecting cells at 1500 ϫ g for 10 min and washing by suspension in ice-cold phosphatebuffered saline and centrifugation. Cells were lysed in 30 ml of lysis buffer (10 mM imidazole-HCl, pH 7, 20 mM potassium phosphate, pH 7, 150 mM NaCl, 1% Nonidet P-40, 1 mM Pefabloc, 1 M leupeptin, 1 mM pepstatin, 1 mM dithiothreitol, 0.1% 2-mercaptoethanol, and 10% glycerol). Cell lysate was clarified by centrifugation at 100,000 ϫ g for 30 min at 4°C. The supernatant was added to 1 ml of Ni-NTA-agarose (Qiagen) and mixed for 16 -24 h at 4°C. Agarose resin was washed with 10 -15 volumes of wash buffer (10 mM imidazole-HCl, pH 7, 20 mM potassium phosphate, pH 7, 500 mM NaCl, 1 mM Pefabloc, 1 M leupeptin, 1 mM pepstatin, 1 mM dithiothreitol, 0.1% 2-mercaptoethanol, and 10% glycerol) at 4°C. His-tagged protein was eluted using stepwise increasing concentrations of imidazole of 5 ml at each step: 50, 100, 200, and 350 mM. Samples were then analyzed by SDS-PAGE and immunoblotted with anti-His tag antibody (Santa Cruz Biotechnology). Samples were pooled and dialyzed against the buffer (50 mM MOPS, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM MgCl 2 , 0.1 mM MnCl 2 , 1 mM dithiothreitol, 0.1% 2-mercaptoethanol, 10% glycerol, and 0.02% Brij-35) and stored at Ϫ20°C.
Phosphatase Activity and Inhibition Assays-Assays with p-nitrophenyl phosphate (pNPP) as substrate were run as described previously (28) , and protein levels were normalized based on anti-His blotting with quantitation done using the Odyssey (LI-COR) infrared scanner and software. Assays with MBP (Sigma) as substrate used 32 P-MBP made using recombinant MAPK as kinase and 32 P-ATP. MBP (100 g) was radiolabeled using ϳ10 Ci (5000 dpm/pmol) at 30°C for 2-4 h followed by overnight incubation at 4°C. The kinase reaction was terminated by adding trichloroacetic acid to a final concentration of 10% and incubating on ice for 30 -45 min. Precipitated protein was collected by centrifugation at 13,800 ϫ g for 10 min at 4°C in a microcentrifuge and washed three times with ice-cold 15% trichloroacetic acid. Following the last wash, the pellet was washed two times with ice-cold acetone and then allowed to air dry. The pellet was dissolved in 20 mM MOPS, pH 7.5, 50 mM NaCl, 1 mM MgCl 2 , 1 mM dithiothreitol, 0.1% 2-mercaptoethanol, 10% glycerol, and 0.1 mg/ml bovine serum albumin and stored at Ϫ20°C. To determine the concentration of 32 P-MBP, a 2-l aliquot of the substrate was counted in a scintillation counter.
Assays used 10 mM pNPP or 2 M 32 P-MBP as substrates when testing OA (Alexis Biochemical), MCLR (Alexis Biochemical), calyculin A (Calbiochem), or cantharidin (Calbiochem) inhibition. All inhibitors were dissolved in Me 2 SO, and controls were assayed with Me 2 SO alone. Inhibitor concentra-tions were calculated based on stock solutions made by dissolving the entire commercial sample in Me 2 SO.
Multiplexed Phospho-site Analysis-COS7 cells were transfected with empty vector or (HA) 3 -␣4 (wild-type murine) using FuGENE 6. Cells were incubated for 24 h and lysed into 1% Nonidet P-40 buffer (50 mM MOPS, pH ϳ7.4, 150 mM NaCl, 1% Nonidet P-40, 1 M MCLR, 1 mM sodium orthovandate, 10 g/ml leupeptin, 10 g/ml pepstatin, 1 mM Pefabloc SC, and 1 mM dithiothreitol). Extracts were clarified by centrifugation at 14,000 rpm for 15 min. Protein concentrations were determined using the BCA method (Pierce), and samples were then diluted using 2ϫ SDS sample buffer to a final concentration of 1.0 mg/ml and boiled for 5-10 min. Approximately, 20 g of extracts were separated on a 10% SDS-PAGE and immunoblotted using anti-␣4. Samples were then sent to Kinexus, Inc. for multiplexed phospho-site analysis using Kinetworks Phospho-site Screen 1.3.
Statistical
Analysis-Analyses were done using Microsoft Excel to determine averages and S.D. Numbers were imported into SigmaPlot 9.0, and Michaelis-Menten and Lineweaver-Burke plots were made using the Enzyme Kinetics Module v1.2 (SigmaPlot). The data were analyzed using nonlinear least-fit squares, and best-fit lines were plotted.
RESULTS
We prepared active recombinant PP6 and PP2A. The human proteins are 57% identical in amino acid sequence (NP_002712 and NP_ 002706, respectively) and share about 40% identity with PP1 (Fig. 1) . The ␤12-13 loop that is known to determine sensitivity to toxins differs in sequence between PP1 and PP6-PP2A (Fig. 1 (26) . These are not basic residues in PP6 catalytic subunit. The human cDNA for PP6 and PP2A was cloned into pFastBac plasmids that were transformed into DH10Bac bacteria to produce bacmids that were used to transfect Sf9 cells to produce baculovirus. The virus was amplified twice in Sf9 cells to obtain high titer stock (10 8 pfu/ml), and Sf9 cells infected at a multiplicity of infection of 5 were grown in 300-ml cultures in spinner flasks for 48 -60 h until the cells appeared swollen and rounded by phase microscopy. Cells were harvested, washed, and lysed, and extracts were applied to Ni-NTA. Proteins were eluted by step gradient of increasing imidazole concentration, dialyzed, and concentrated by ultrafiltration on YM-30 membranes. The overall yield of soluble PP6 was 1-2 g, and PP2A was ϳ10 -15 g. This only represented the soluble fraction of the expressed protein, and at least 20 times more protein was recovered in the insoluble pellets following the extraction, based on immunoblotting with anti-His 6 antibodies (not shown).
Enzyme Kinetics and Toxin Inhibition of Monomeric PP6 and PP2A-The soluble recombinant His 6 -PP6 and His 6 -PP2A proteins were assayed using pNPP. Equal amounts of PP6 and PP2A were added to the assays and their absolute concentrations determined by immunoblotting relative to a standard His 6 -tagged protein ( Fig. 2A) . With pNPP both FIGURE 1. Protein sequence alignment of PP1, PP2A, and PP6. Protein sequences were aligned in DNAStar program using the Clustal alignment method. Reverse printed regions show positions where two of three sequences were identical. The catalytic site is marked with a broken line, and the boxed residues are required for A subunit binding to PP2A. Toxin contact site residues that are similar in PP1, PP2A, and PP6 are denoted by closed circles. Toxin contact sites that are different in PP1, PP2A, and PP6 are denoted by asterisks.
His 6 -PP6 (Fig. 2B) and His 6 -PP2A (Fig. 2C) showed identical activity and saturation with increasing substrate concentration. Lineweaver-Burke plots using nonlinear least-fit squares showed linear kinetics with calculated K m of 10 mM and V max of 110 mol/min/mg. The phosphatase activity of His 6 -PP6 and His 6 -PP2A measured with pNPP as a substrate FIGURE 2. Kinetics of pNPP hydrolysis by His 6 -PP6 and His 6 -PP2A. Proteins were assayed using pNPP as a substrate. A, an anti-His 6 immunoblot of recombinant His 6 -PP2A and His 6 -PP6 shows equal amounts of protein in each reaction. B, the Lineweaver-Burke plot with His 6 -PP6 and a Michaelis-Menten plot as an inset. C, the Lineweaver-Burke plot with His 6 -PP2A and a Michaelis-Menten plot as an inset. The K m for both PP6 and PP2A with pNPP is ϳ10 mM. showed identical IC 50 values with a variety of structurally diverse small molecule inhibitors (Fig. 3) . Okadaic acid (Fig.  3A) and microcystin-LR (Fig. 3B) inhibited His 6 -PP2A and His 6 -PP6 with an IC 50 of 0.1 nM. Calyculin A (Fig. 3C ) was less effective with an IC 50 of 1 nM, whereas cantharidin (Fig.  3D ) was ϳ1000-fold less potent with an IC 50 of 8 M. These results demonstrated that different inhibitors are equally effective at inhibition of His 6 -PP6 and His 6 -PP2A catalytic subunits when using the substrate pNPP.
Inhibition of His 6 -PP6 and His 6 -PP2A by various toxins was nonidentical when phosphatase activity was assayed with MBP as a substrate. With 32 P-MBP as substrate, His 6 -PP2A had slightly higher activity than His 6 -PP6, as the substrate concentration increased (Fig. 4) . There was not a plateau in velocity at the highest substrate concentrations tested, but LineweaverBurke plots showed linear kinetics and yielded a K m of 26 and 25 M and V max of 2.2 and 2.8 mol/min/mg for PP6 (Fig. 4A) and PP2A (Fig. 4B) , respectively. With MBP as substrate, PP6 was significantly more sensitive than PP2A to each of the toxin inhibitors. For okadaic acid (Fig. 5A) , the IC 50 was 2 nM with PP6 (solid line) and 10 nM with PP2A (broken line). For MCLR (Fig. 5B) , the IC 50 was 0.6 nM with PP6 (solid line) and 2 nM with PP2A (broken line). For calyculin A (Fig. 5C ), the IC 50 was 2 nM with PP6 (solid line) and ϳ10 nM with PP2A (broken line). For high affinity inhibitors, there is a concern that inhibition can reflect titration of stoichiometric enzyme⅐inhibitor complexes. However, the IC 50 values for various inhibitors were different with the two substrates tested at the same enzyme concentration, and therefore they were not simply dependent on the amount of enzyme in the assay. In these assays we estimated, 0.2 pmol of enzyme was present; therefore at the IC 50 concentrations, there was Ͼ25-fold excess of inhibitor over enzyme. Furthermore, His 6 -PP6 was more sensitive to each of the inhibitors, relative to His 6 -PP2A at the same concentrations.
The increased inhibitor sensitivity of His 6 -PP6 compared with His 6 -PP2A, when assayed with MBP as substrate, could have been because of allosteric interactions of the substrate with the phosphatases. To test this idea we assayed both His 6 -PP6 and His 6 -PP2A with various proteins added to the assay, using pNPP as a substrate to test for any shift in the IC 50 for okadaic acid. The assays were performed with preincubation of the phosphatases plus 10 M unphosphorylated MBP, 10 M histone H1 as another polycationic protein, or 10 M glutathione S-transferase as a control or with buffer alone followed by addition of pNPP substrate. The inhibition of His 6 -PP6 and His 6 -PP2A by okadaic acid was unaffected by addition of any of these proteins (not shown). Therefore, we concluded that the difference in IC 50 between His 6 -PP6 and His 6 -PP2A with the substrate MBP was not because of allosteric effects. Our conclusion was that the higher sensitivity of His 6 -PP6 compared with His 6 -PP2A to inhibitors was an evidence of a structural difference between these phosphatases detected by reaction with the MBP substrate.
Properties of PP6 and PP2A Heterodimers with ␣4-We copurified and assayed heterodimers of His 6 -tagged ␣4 plus untagged PP6 or PP2A. Separate viruses for each subunit were used to co-infect Sf9 cells, and the heterodimers were purified by Ni-NTA metal ion affinity chromatography. Coomassie staining showed composition of the heterodimers (Fig. 6A) . The untagged catalytic subunits were recovered in less than stoichiometric amount relative to His 6 -␣4, but this strategy insured that all the PP6 or PP2A in the preparations was bound to His 6 -␣4. When we expressed His 6 -␣4 alone as a control, no endogenous Sf9 cell PP6 or PP2A was co-purified as judged by Coomassie staining or by anti-PP6 and -PP2A immunoblotting (not shown); therefore the catalytic subunits in the heterodimers were human PP6 and PP2A. Interestingly, co-expression of PP6 or PP2A with His 6 -␣4 resulted in most of the phosphatase catalytic subunits being recovered in much higher yield and in the soluble fraction, instead of the insoluble fraction, as we observed when the phosphatases were expressed alone (see above). His 6 -␣4 could assist in the folding of the nascent phosphatase polypeptides, or we think it more likely that His 6 -␣4 binds to the phosphatases to stabilize conformation and protect them from unfolding and accumulation in an insoluble fraction.
Even though co-expression with His 6 -␣4 increased the yields of soluble PP6 and PP2A catalytic subunits, it was surprising to us that these heterodimers exhibited essentially no phosphatase activity with the small molecule pNPP as substrate. One might conclude that ␣4 acts as a phosphatase inhibitor. However, the His 6 -␣4⅐PP6 heterodimer did have a detectable, low level of phosphatase activity with MBP as substrate (Fig. 6B ) with lower K m and reduced V max compared with the monomeric His 6 -PP6. The kinetics of the heterodimers with phospho-MBP as substrate were distinctively different, with about Ͼ100-fold higher V max for His 6 -␣4⅐PP2A relative to the His 6 -␣4⅐PP6 heterodimer (Fig. 6C) . The Michaelis-Menten plot for His 6 -␣4⅐PP2A did not show saturation up to 25 M, and an estimate of K m was 250 M. These phosphatases behaved dramatically differently when bound to the same regulatory subunit.
Furthermore, there was a 5-fold difference in inhibition by okadaic acid between His 6 -␣-4⅐PP6 and His 6 -␣4⅐PP2A with IC 50 of ϳ40 and ϳ7 nM, respectively (Fig. 7) . This was the reverse of the situation with the monomeric His 6 -tagged catalytic subunits (Fig. 5A) , where the IC 50 for PP6 was 5-fold lower than for PP2A. We note that the IC 50 values for okadaic acid in these assays with His 6 -PP2A monomer and His 6 -␣4⅐PP2A was about the same (10 and 7 nM). Thus, association of PP2A with ␣4 did not much alter its inhibition by okadaic acid. On the other hand, binding of His 6 -␣4 to PP6 produced a 20-fold shift in the IC 50 value for okadaic acid. Our interpretation of this result was that ␣4 binding to PP6 produced conformational changes in the phosphatase active site to reduce activity and diminish sensitivity to inhibitors.
Differential Effects of ␣4 on Protein Phosphorylation-We transiently overexpressed (HA) 3 -␣4 in COS7 cells and tested for changes in phosphorylation status of 27 different sites in well known signaling pathways (Fig. 8) . The level of tagged ␣4 expressed was about the same as the amount of endogenous ␣4 as detected by anti-␣4 immunoblotting (Fig. 8A) . Table 1 (Fig. 8, B and C) . Some proteins were not affected by expression of exogenous ␣4, shown with circles in Fig. 8, B We concluded that ␣4 promotes dephosphorylation of p38, c-Jun, CREB, GSK3␣, Rb, and PKB/Akt and inhibits phosphatase activity toward MEK1/2, PKR, and STAT3.
DISCUSSION
PP6 belongs to the type 2A family of phosphatases (PP2A, PP4, PP6) based on sequences that are 50% identical; therefore one might expect that these phosphatases would have similar biochemical and enzymatic properties. No comparison of PP6 and PP2A has been possible to date because neither PP6 partially purified from bovine testes (14) nor recombinant PP6 expressed in bacteria (16) exhibits measurable phosphatase activity in biochemical assays. Here we show that a small fraction of His 6 -PP6 expressed in Sf9 cells was recovered in a soluble, active monomeric form, and we measured its activity relative to recombinant His 6 -PP2A prepared in the same way. Recombinant PP6 and PP2A had identical kinetics with both pNPP and phosphorylated MBP as substrates even though the K m for these substrates differed by 400-fold. As one might have predicted, the IC 50 for a structurally diverse set of natural toxins (okadaic acid, microcystin-LR, calyculin A, cantharidin) known to bind at the active site of protein phosphatases was identical for PP6 and PP2A when using the small molecule pNPP as substrate. What was unexpected was the 5-fold difference in inhibition of PP6 relative to PP2A using this same set of toxins when assayed with MBP as substrate. This was not simply because of adding a basic protein to the assay as neither unphosphorylated MBP nor histone H1 shifted the IC 50 for toxins. PP6 was more sensitive to the inhibitors with a protein substrate, and in living cells and tissues PP6 may be the preferential target for these toxins. Inhibition of PP6 may therefore account for some of the many reported biological effects of the toxins. The results indicate to us that there are structural differences between the active sites of monomeric PP6 and PP2A that define a distinctive chemical space that might be exploited in the design of specific inhibitors.
The structure of PP1 bound to okadaic acid (5) has been determined, which allowed us to thread the PP6 and the PP2A protein sequences onto this PP1 backbone. In these models we focused our attention on the ␤12-13 loop (Fig. 1) because previous mutagenesis studies showed that Tyr 271 in PP1 (Tyr 265 in PP2A, Tyr 261 in PP6) in the ␤12-13 loop is critical for high affinity interaction with toxins at the phosphatase active site (29 5A ). On the other hand, His 6 -␣4⅐PP6 (closed circles) is less sensitive to OA with a 10-fold decrease of IC 50 versus monomeric PP6 (see Fig. 5A ).
and human. We speculate that the Trp at this position could produce subtle differences the ␤12-13 loop that account for enhanced toxin binding to PP6. Analysis of the structures of PP1 bound to active site inhibitors identifies multiple surface residues in contact with the toxins (30 (Fig. 1, closed circles) Genetic studies in yeast have shown that the PP2A, PP4, and PP6 phosphatases (yeast Pph21/22, Pph3, and Sit4, respectively) have individual functions, and these genes do not complement one another. This is probably in part because of the binding of different regulatory subunits to each of the phosphatases. There are surface determinants for each phosphatase catalytic subunit to recognize unique regulatory subunits, and we have mapped residues in PP2A that are critical for binding of the scaffold A subunit (26) . The mammalian protein ␣4 (Tap42 in yeast) is unusual because it binds all three type 2A phosphatases as found in a yeast 2-hybrid assay (22) . Here we found that heterodimers of His 6 -␣4 with either PP6 or PP2A were not active with pNPP as substrate. This is interesting because pNPP is a small molecule utilized as a universal phosphatase substrate. One might therefore mistakenly conclude that ␣4 is a type 2A phosphatase inhibitor protein. Tap42, the homologue of ␣4 in yeast, has been considered a phosphatase inhibitor (18 -21) . However, ␣4 heterodimers with PP6 or PP2A were active with MBP as substrate and inhibited by active site-directed toxins. This argues that binding of ␣4 to the phosphatase catalytic subunit allosterically modifies rather than occludes the active site. The allosteric effect of ␣4 was quite different for PP6 compared with PP2A. When bound to ␣4, the activity of PP6 was severely reduced in contrast to increased activity (V max ) of PP2A bound to ␣4. Our results demonstrate that a single regulatory subunit can recognize two kinetically identical catalytic subunits to induce different allosteric effects that alter enzyme activity and active site toxin binding. Our biochemistry results in part explain published observations that seem at odds, i.e. that Tap42 inhibits Sit4 but ␣4 bound to PP2A is active. It is remarkable that a common subunit exerts opposite effects on two closely related catalytic subunits. This can produce distinctive increases and decreases in phosphorylation depending on the substrates. As a test of this predication, we transiently overexpressed ␣4 and screened for changes in over two dozen well known phosphorylation events. We observed increased and decreased phosphorylation as well as no change in phosphoryl- expressing (HA) 3 -␣4. By blotting for ␣4, the levels of (HA) 3 -␣4 can be compared with endogenous levels of ␣4. B and C, the multiplexed immunoblots of cell extracts for empty vector and (HA) 3 -␣4, respectively, from the Kinexus screen with lanes marked from 2 to 20 (for list refer to Table 1 ). The open circles are unchanged phosphoproteins, the dotted line squares represent decreased phosphorylation, and the solid squares denote enhanced phosphorylation. This concept has important implications for understanding the regulation of protein phosphatases. Phosphatase subunits are frequently called "targeting" subunits because they tether catalytic subunits, especially PP1, to intracellular structures such as glycogen or myofilaments. However, binding of regulatory subunits to the catalytic subunits allosterically modifies the kinetic properties of the phosphatase. Binding of A subunit, generally regarded as a scaffold partner, has been shown to allosterically modify the kinetics of PP2A (31) . We suggest that the association of ␣4 allosterically regulates type 2A phosphatases but in opposite ways. Binding involves recognition of residues common to PP6 and PP2A, but the interaction also engages residues different in PP6 compared with PP2A and thereby produces different active site conformations. The nature of the subunit interface and the resulting changes at the active site remain to be determined experimentally. The changes in enzyme kinetics documented here may help to understand the complex and seemingly contradictory effects of ␣4 (and Tap42) in cells.
